Together, these data establish a compelling therapeutic rationale for rapid clinical evaluation of dual CDK9/2 inhibitors and specifically the oral developmental drug CYC065 in MYCN-driven high-risk NB. The gene discussed is MYCN; the disease is neuroblastoma.